Evaluating heart health factors after liver transplantation
Factors Associated With Short-Term Major Adverse Cardiovascular Events After Liver Transplantation
This study is testing if advanced heart imaging techniques can help doctors better understand and manage heart risks in patients getting a liver transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 2 sites (Guangzhou, Guangdong and 1 other locations) |
| Trial ID | NCT06290154 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the cardiovascular outcomes in patients undergoing liver transplantation, focusing on the impact of various clinical and echocardiographic parameters. It aims to determine whether advanced echocardiographic techniques, such as speckle tracking and tissue Doppler imaging, can enhance preoperative risk assessment for patients with end-stage cirrhosis. By analyzing these factors, the study seeks to improve understanding of cardiac risks associated with liver transplantation and potentially guide better clinical decisions.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with end-stage cirrhosis who are scheduled for liver transplantation.
Not a fit: Patients with significant cardiac dysfunction or severe structural heart abnormalities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved preoperative risk stratification and better cardiac outcomes for liver transplant patients.
How similar studies have performed: While there is ongoing research in this area, the specific use of comprehensive echocardiographic multiparameters for risk stratification in liver transplant patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years, * End-stage cirrhosis patients who will receive liver transplantation, * Patients voluntarily take part in the study and write informed consent. Exclusion Criteria: * Decreased left ventricular systolic function (ejection fraction \<45%), * Significant uncorrectable structural cardiac abnormalities (eg, symptomatic coronary heart disease, advanced cardiomyopathy, severe valvular disease, severe congenital heart disease, etc), * Uncontrolled pulmonary hypertension defined as pulmonary arterial systolic pressure ≧ 35mm Hg at rest despite maximal medical management, * Circulatory or respiratory system with a score of 4 based on the preoperative Organ Dysfunction (CLIF-SOFA) score, * Second-time liver transplantation, * Combined organ transplantation, * Satisfactory quality echocardiography could not be obtained before operation.
Where this trial is running
Guangzhou, Guangdong and 1 other locations
- The Third Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
- the Third Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jia Liu, Dr
- Email: 395847953@qq.com
- Phone: 15920190962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.